Mednow to Host Quarterly Conference Call on Wednesday, December 22, 2021 at 8:30 a.m. EST on its First Quarter 2022 Financial Results and Company Update

TORONTO, December 20, 2021– (BUSINESS WIRE) – Mednow Inc. (“Mednow” or the “Society“) (TSXV: MNOW), Canada’s on-demand virtual pharmacy, is pleased to announce that the Company will host its quarterly conference call on Wednesday, December 22, 2021 at 8:30 a.m. EST. The conference call will cover its first quarter 2022 financial results and an update.

During the call, the Mednow team will provide an update on Mednow’s national expansion, recent strategic partnerships, milestones, M&A activity, and first quarter 2022 financial results. Please use one of the two call numbers provided below five minutes before the scheduled start time and specify the Mednow call.

Conference call details:

Canada / United States Toll Free: 1-800-319-4610

International number: 1-604-638-5340

The conference call will be available on our website at: for playback in a few business days.

About Mednow Inc.

Mednow is a virtual access healthcare technology company with exceptional care. Designed with access and quality of care in mind, offers virtual pharmacy and telemedicine services, as well as home visits to the doctor, in a practical manner and through an interdisciplinary approach to patient care. health centered on the patient experience. Mednow’s services include free home delivery of medications, a user-friendly interface for easy download, transfer and renewal of prescriptions, access to healthcare professionals through an intuitive chat experience, a specialized PillSmart ™ system that packages prescriptions and vitamins by date and time. , and medical consultations.

To find out more, follow Mednow on Facebook, Twitter, LinkedIn and Instagram, as well as visit

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

See the source version on


Investor Relations Contact:
Lucy chitilian
[email protected]

Michael P. Boser